Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Figure 1

Survival analysis. The survival analysis was performed with the Kaplan-Meier method, and a comparison of the survival curves was performed with the log-rank test. (a) The median survival time (MST) from the first vaccination of PPV was 184 days in 42 patients. (b) The patients with a JIS score of 3 (MST, 189 days) did not show significantly different survival, compared to those with a JIS score of 4 or 5 (MST, 164 days) (). (c) Combination therapy with sorafenib did not affect OS (). (d) Patients with decreased TM (tumor markers), AFP, or DCP, after vaccination (MST, 286 days) showed longer survival than those without it (MST, 180 days) ().

(a)

(b)

(c)

(d)